Abstract: A new polymorphic form of (±)7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid is disclosed. The compound has a melting point of 80° C. to 82° C. and is a leukotriene B4 antagonist (“LBA”). The compound is useful for diminishing the adverse effects (e.g. vascular leakage syndrome) of IL-2 treatment.

Abstract: A method of treating an immunologic, proliferative, or infectious disease in a warm-blooded animal is disclosed. The method comprises administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal, which dosage and activity for the disease state treated is higher than would be well-tolerated based on data for non-omega IFN's. The omega IFN is administered alone or in combination with a therapeutically effective amount of at least one adjunctive therapeutic agent. Also disclosed is an article of manufacture useful for treating an immunologic, proliferative, or infectious disease, which article comprises (1) omega IFN in a form suitable for administering a therapeutically effective amount of the omega IFN to the subject in order to induce the desired therapeutic response (2) instructions for administering the omega IFN as desired, that is higher than would be well-tolerated based on data for non-omega IFNs.

Abstract: The present invention relates to methods of protecting against injury to hair follicles in a mammal by administering an effective amount of butyric acid or a biologically active butyric acid derivative. In particular, this invention relates to the use of cell differentiation-inducing butyric acid derivatives to protect against hair loss in cancer patients undergoing chemotherapy and/or radiation therapy.